3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
5
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Gynecologic
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
1023
Carboplatin
964
Paclitaxel
933
Gemcitabine
794
Cisplatin
751
Docetaxel
683
Bevacizumab
609
Pemetrexed
502
Nivolumab
487
Cyclophosphamide
471
Capecitabine
461
Fluorouracil
418
Dexamethasone
403
Rituximab
372
Oxaliplatin
348
Injections
345
atezolizumab
298
Trastuzumab
298
Leucovorin
288
Cetuximab
282
Irinotecan
268
130-nm albumin-bound paclitaxel
254
Prednisone
245
Doxorubicin
240
Ipilimumab
226
Lenalidomide
220
fludarabine
218
Fulvestrant
217
durvalumab
205
Erlotinib Hydrochloride
188
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Interventional
×
Mebendazole
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn
NCT03628079
2020-01-22
RepoMeb
Repos Pharma
Phase 1/2
Terminated
11 enrolled